Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	transmembrane receptor protein tyrosine kinase activity	EGFR ROS1 FGFR2 EPHA4 EPHB1	8.68e-05	65	138	5	GO:0004714
Domain	PROTEIN_KINASE_TYR	LMTK2 EGFR ROS1 FGFR2 EPHA4 EPHB1	8.31e-05	97	138	6	PS00109
Domain	Tyr_kinase_AS	LMTK2 EGFR ROS1 FGFR2 EPHA4 EPHB1	8.31e-05	97	138	6	IPR008266
Domain	AT_hook	PRR12 BAZ2A KMT2A	2.06e-04	16	138	3	PF02178
Domain	Aldolase_II	ADD1 ADD3	3.22e-04	4	138	2	SM01007
Domain	Aldolase_II/adducin_N	ADD1 ADD3	3.22e-04	4	138	2	IPR001303
Domain	Aldolase_II	ADD1 ADD3	3.22e-04	4	138	2	PF00596
Domain	-	ADD1 ADD3	3.22e-04	4	138	2	3.40.225.10
Domain	Pkinase_Tyr	LMTK2 EGFR ROS1 FGFR2 EPHA4 EPHB1	3.94e-04	129	138	6	PF07714
Domain	Tyr_kinase_cat_dom	EGFR ROS1 FGFR2 EPHA4 EPHB1	4.91e-04	88	138	5	IPR020635
Domain	TyrKc	EGFR ROS1 FGFR2 EPHA4 EPHB1	4.91e-04	88	138	5	SM00219
Pathway	WP_ENDOMETRIAL_CANCER	FOS CASP9 EGFR FGFR2 POLK SOS2	2.38e-06	63	87	6	M39623
Pubmed	Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.	ARHGAP32 DNAJC13 IRS4 SIPA1L3 ZNF280C ZDHHC5 LMTK2 TRIOBP KIAA1549 RNF213 AP3B1 CEP350 TTC7B NUP155 SMG7 EGFR FMN2 MPHOSPH9 HADHB HERC1 NEURL4 PRRC2B ILKAP	3.87e-11	1049	140	23	27880917
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: IV. The complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	SH3TC2 ARHGAP32 ARHGEF28 SIPA1L3 ZDHHC5 RNF213 ZNF407 ATP10A CEP350 PRR12 VPS13D TNRC18 NEURL4 TRAPPC9	1.41e-08	493	140	14	15368895
Pubmed	Identifications of novel host cell factors that interact with the receptor-binding domain of the SARS-CoV-2 spike protein.	SAMD9 ARHGEF28 AP3B1 MAST2 ANKZF1 SBNO2 PRR12 EIF2D MAP7D1 NUP155 GORASP1 KMT2A CMTR2 PLXNB1 PRRC2B	6.42e-08	650	140	15	38777146
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	SYNRG ARHGAP32 IRS4 ARHGEF28 SIPA1L3 AAK1 LMTK2 MAST2 CEP350 VPS13D MAP7D1 FMN2 KMT2A MPHOSPH9 TRAPPC9 BICC1	4.25e-07	861	140	16	36931259
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	SYNRG PCNX3 PPRC1 SIPA1L3 ZDHHC5 AKNA LMTK2 MAST2 SBNO2 PKMYT1 PRR12 TNRC18 ZNF592 KCNH2 FGFR2 HERC1 TRAPPC9 PRRC2B	5.25e-07	1105	140	18	35748872
Pubmed	Pro-prion, as a membrane adaptor protein for E3 ligase c-Cbl, facilitates the ubiquitination of IGF-1R, promoting melanoma metastasis.	VPS37A NBEAL1 TUT1 MAST2 CEP350 RIOX2 TNRC18 SMG7 EGFR SKOR2 PDE4DIP HADHB TARBP2 PRRC2B	8.26e-07	689	140	14	36543142
Pubmed	Mammalian homologues of the Drosophila Son of sevenless gene map to murine chromosomes 17 and 12 and to human chromosomes 2 and 14, respectively.	FOS LAMA1 SOS2	2.21e-06	7	140	3	8276400
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	KLF8 DNAJC13 VPS37A DYM SIPA1L3 TOM1L1 FRMPD1 AAK1 TRIOBP RNF213 ATP8B1 ATP10A SBNO2 TNRC18 SMG7 EGFR RERE POLK TRAPPC9 SOS2	2.32e-06	1489	140	20	28611215
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	RBBP6 KIAA1549 RNF213 MAST2 SLC40A1 TTC7A ZNF469 MAP7D1 SMG7 ZNF592 BAZ2A FMN2 BICRAL RERE LONRF3 TARBP2 PRRC2B	2.75e-06	1116	140	17	31753913
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	ARHGAP32 DNAJC13 OXR1 SIPA1L3 AAK1 KIAA1549 AP3B1 JMY ADD1 ADD3 DZANK1 MAP7D1 TTC7B VCAN PDE4DIP KMT2A HADHB TRAPPC9 PRRC2B	5.03e-06	1431	140	19	37142655
Pubmed	Soluble SORLA Enhances Neurite Outgrowth and Regeneration through Activation of the EGF Receptor/ERK Signaling Axis.	FOS EGFR EPHA4	5.27e-06	9	140	3	32601248
Pubmed	A Global Analysis of the Receptor Tyrosine Kinase-Protein Phosphatase Interactome.	DNAJC13 LMTK2 MUC16 AASDH MAST2 EGFR FGFR2 HERC1 EPHA4 ILKAP	8.43e-06	420	140	10	28065597
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	ARHGAP32 DNAJC13 SIPA1L3 TRPC4 AAK1 TRIOBP ADD1 DZANK1 MAP7D1 KCNJ10 PDE4DIP UNC79 NEURL4 PRRC2B EPHA4	8.48e-06	963	140	15	28671696
Pubmed	A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer Therapy.	ARHGAP32 IRS4 ZDHHC5 TRIOBP ADD1 ADD3 TTC7B NUP155 EGFR EPHA4	8.61e-06	421	140	10	36976175
Pubmed	Ephrin/ephrin receptor expression during early stages of mouse inner ear development.	NEUROG1 EPHA4 EPHB1	1.37e-05	12	140	3	21465626
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	TTF2 SYNRG IRS4 RBBP6 AP3B1 ADD1 ADD3 SMG7 BAZ2A KMT2A PRRC2B	1.49e-05	549	140	11	38280479
Pubmed	Epidermal growth factor induces tyrosine phosphorylation, membrane insertion, and activation of transient receptor potential channel 4.	TRPC4 EGFR	1.61e-05	2	140	2	16144838
Pubmed	Identification of New Genetic Clusters in Glioblastoma Multiforme: EGFR Status and ADD3 Losses Influence Prognosis.	ADD3 EGFR	1.61e-05	2	140	2	33172155
Pubmed	Effects of genetic variation in adducin on left ventricular diastolic function as assessed by tissue Doppler imaging in a Flemish population.	ADD1 ADD3	1.61e-05	2	140	2	18475162
Pubmed	Regulation of anoikis resistance by NADPH oxidase 4 and epidermal growth factor receptor.	NOX4 EGFR	1.61e-05	2	140	2	28081539
Pubmed	Versican G3 domain regulates neurite growth and synaptic transmission of hippocampal neurons by activation of epidermal growth factor receptor.	EGFR VCAN	1.61e-05	2	140	2	16648628
Pubmed	Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling.	EGFR VCAN	1.61e-05	2	140	2	21079779
Pubmed	RME-8 regulates trafficking of the epidermal growth factor receptor.	DNAJC13 EGFR	1.61e-05	2	140	2	18307993
Pubmed	Promoter region of the murine fibroblast growth factor receptor 2 (bek/KGFR) gene.	EGFR FGFR2	1.61e-05	2	140	2	1408137
Pubmed	The Impact of Human Mammary Tumor Virus (HMTV) on the Expression of Epidermal Growth Factor Receptor (EGFR) and Death-Domain Associated Protein (DAXX) in Breast Carcinoma Tissues.	DAXX EGFR	1.61e-05	2	140	2	37396746
Pubmed	Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.	EGFR ROS1	1.61e-05	2	140	2	24349229
Pubmed	Increased expression of phosphorylated adducin in tumor cells.	ADD1 ADD3	1.61e-05	2	140	2	32237935
Pubmed	Adducins regulate remodeling of apical junctions in human epithelial cells.	ADD1 ADD3	1.61e-05	2	140	2	20810786
Pubmed	Trans-activation response (TAR) RNA-binding protein 2 is a novel modulator of transient receptor potential canonical 4 (TRPC4) protein.	TRPC4 TARBP2	1.61e-05	2	140	2	24563462
Pubmed	Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.	EGFR FGFR2	1.61e-05	2	140	2	24550739
Pubmed	Decreased HCRP1 promotes breast cancer metastasis by enhancing EGFR phosphorylation.	VPS37A EGFR	1.61e-05	2	140	2	27311861
Pubmed	SR protein kinases promote splicing of nonconsensus introns.	DNAJC13 RBBP6 SIPA1L3 ZDHHC5 MAST2 ATP10A MAP7D1 ZNF592 PRRC2B	1.68e-05	361	140	9	26167880
Pubmed	Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.	EGFR FGFR2 EPHA4 EPHB1	2.05e-05	40	140	4	30898150
Pubmed	The protein tyrosine kinase family of the human genome.	EGFR ROS1 FGFR2 EPHA4 EPHB1	2.22e-05	83	140	5	11114734
Pubmed	Interactomes of Glycogen Synthase Kinase-3 Isoforms.	SYNRG SIPA1L3 ZDBF2 ADD1 ADD3 CEP350 VPS13D	2.34e-05	209	140	7	36779422
Pubmed	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.	ZDHHC5 RBM28 AP3B1 CEP350 MAP7D1 GORASP1 PDE4DIP PRRC2B	2.97e-05	298	140	8	32353859
Pubmed	A Degradation Motif in STAU1 Defines a Novel Family of Proteins Involved in Inflammation.	SYNRG DNAJC13 AAK1 TRIOBP DAXX AP3B1 ADD1 CEP350 RIOX2 MAP7D1 SMG7 PRRC2B	3.90e-05	724	140	12	36232890
Pubmed	The human cytoplasmic dynein interactome reveals novel activators of motility.	TTF2 SYNRG ARHGAP32 SIPA1L3 AAK1 CASP9 MAST2 CEP350 EIF2D SMG7 MPHOSPH9 NEURL4 PRRC2B	4.36e-05	853	140	13	28718761
Pubmed	Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targets.	AKNA SYBU ANKZF1 MAP7D1 TTC7B PDE4DIP NEURL4	4.67e-05	233	140	7	37704626
Pubmed	Both EGFR kinase and Src-related tyrosine kinases regulate human ether-à-go-go-related gene potassium channels.	EGFR KCNH2	4.81e-05	3	140	2	18617000
Pubmed	Identification of epidermal growth factor receptor and its inhibitory microRNA141 as novel targets of Krüppel-like factor 8 in breast cancer.	KLF8 EGFR	4.81e-05	3	140	2	26025929
Pubmed	Immunohistochemical studies on the expression and estrogen dependency of EGF and its receptor and C-fos proto-oncogene in the uterus and vagina of normal and neonatally estrogen-treated mice.	FOS EGFR	4.81e-05	3	140	2	8800404
Pubmed	Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.	EGFR ROS1	4.81e-05	3	140	2	33053439
Pubmed	A yeast three-hybrid method to clone ternary protein complex components.	EGFR SOS2	4.81e-05	3	140	2	8923966
Pubmed	Aging results in reduced epidermal growth factor receptor signaling, diminished olfactory neurogenesis, and deficits in fine olfactory discrimination.	LIFR EGFR	4.81e-05	3	140	2	15385618
Pubmed	V3 versican isoform alters the behavior of human melanoma cells by interfering with CD44/ErbB-dependent signaling.	EGFR VCAN	4.81e-05	3	140	2	21078678
Pubmed	Differential expressions of the eph family of receptor tyrosine kinase genes (sek, elk, eck) in the developing nervous system of the mouse.	EPHA4 EPHB1	4.81e-05	3	140	2	7609620
Pubmed	Analysis of the status of EGFR, ROS1 and MET genes in non-small cell lung adenocarcinoma.	EGFR ROS1	4.81e-05	3	140	2	28952227
Pubmed	Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas.	EGFR ROS1	4.81e-05	3	140	2	28063177
Pubmed	Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions.	EGFR ROS1	4.81e-05	3	140	2	35081265
Pubmed	PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.	EGFR ROS1	4.81e-05	3	140	2	30475455
Pubmed	Immunofluorescence localization of an adducin-like protein in the chromosomes of mouse oocytes.	ADD1 ADD3	4.81e-05	3	140	2	1864459
Pubmed	Localization and functional consequences of a direct interaction between TRIOBP-1 and hERG proteins in the heart.	TRIOBP KCNH2	4.81e-05	3	140	2	29507111
Pubmed	Genome-wide association study of major recurrent depression in the U.K. population.	VCAN BICC1	4.81e-05	3	140	2	20516156
Pubmed	High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma.	EGFR ROS1	4.81e-05	3	140	2	32979347
Pubmed	Epistatic interaction between alpha- and gamma-adducin influences peripheral and central pulse pressures in white Europeans.	ADD1 ADD3	4.81e-05	3	140	2	15834281
Pubmed	Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.	EGFR FGFR2	4.81e-05	3	140	2	21173787
Pubmed	Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients.	EGFR ROS1	4.81e-05	3	140	2	32928143
Pubmed	Targeted disruption of the beta adducin gene (Add2) causes red blood cell spherocytosis in mice.	ADD1 ADD3	4.81e-05	3	140	2	10485892
Pubmed	Autosomal recessive polycystic kidney disease epithelial cell model reveals multiple basolateral epidermal growth factor receptor sorting pathways.	EGFR BICC1	4.81e-05	3	140	2	20519437
Pubmed	Role of the adducin family genes in human essential hypertension.	ADD1 ADD3	4.81e-05	3	140	2	15716695
Pubmed	EGFR mutations and ROS1 and ALK rearrangements in a large series of non-small cell lung cancer in South India.	EGFR ROS1	4.81e-05	3	140	2	32881404
Pubmed	Hepatoprotective effects of Methyl ferulic acid on alcohol-induced liver oxidative injury in mice by inhibiting the NOX4/ROS-MAPK pathway.	NOX4 ROS1	4.81e-05	3	140	2	28890346
Pubmed	[Clinicopathological significance in non-small cell lung cancer with mutations and co-mutations of EGFR, ALK and ROS1].	EGFR ROS1	4.81e-05	3	140	2	33677892
Pubmed	ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.	EGFR ROS1	4.81e-05	3	140	2	28743163
Pubmed	EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling.	FOS EGFR	4.81e-05	3	140	2	30361264
Pubmed	EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer.	LIFR EGFR	4.81e-05	3	140	2	32963351
Pubmed	Gly460Trp alpha-adducin mutation as a possible mechanism leading to endolymphatic hydrops in Ménière's syndrome.	ADD1 ADD3	4.81e-05	3	140	2	18667944
Pubmed	Functional coding/non-coding variants in EGFR, ROS1 and ALK genes and their role in liquid biopsy as a personalized therapy.	EGFR ROS1	4.81e-05	3	140	2	33038629
Pubmed	Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.	EGFR ROS1	4.81e-05	3	140	2	30565433
Pubmed	It's not just baby's babble/Babel: recent progress in understanding the language of early mammalian development: a minireview.	EGFR FGFR2	4.81e-05	3	140	2	9890755
Pubmed	Arterial properties in relation to genetic variations in the adducin subunits in a white population.	ADD1 ADD3	4.81e-05	3	140	2	18787518
Pubmed	Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.	EGFR ROS1	4.81e-05	3	140	2	30580372
Pubmed	The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.	MUC16 EGFR	4.81e-05	3	140	2	32016961
Pubmed	The oncogenic ADAMTS1-VCAN-EGFR cyclic axis drives anoikis resistance and invasion in renal cell carcinoma.	EGFR VCAN	4.81e-05	3	140	2	39333870
Pubmed	Ggnbp2 Is Essential for Pregnancy Success via Regulation of Mouse Trophoblast Stem Cell Proliferation and Differentiation.	FOS LIFR EGFR FGFR2	5.43e-05	51	140	4	26764350
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	ZNF280C AAK1 AKNA LMTK2 TRIOBP KIAA1549 NUP155 SMG7 ZNF592 PLXNB1	5.98e-05	529	140	10	14621295
Pubmed	Human transcription factor protein interaction networks.	ARHGAP32 KLF8 IRS4 RBBP6 FOS RBM28 ZFPM2 PRR12 MAP7D1 SMG7 ZNF592 KMT2A HADHB RERE HERC1 TRAPPC9 PRRC2B	6.50e-05	1429	140	17	35140242
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	ARHGAP32 IRS4 RBBP6 ZNF469 TNRC18 NUP155 NFE2L1 NEURL4 SOS2	6.53e-05	430	140	9	35044719
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	SYNRG DNAJC13 RBBP6 AAK1 DAXX ADD1 EIF2D EGFR ZNF592 BAZ2A KMT2A RERE	7.37e-05	774	140	12	15302935
Pubmed	Defining the proximal interaction networks of Arf GTPases reveals a mechanism for the regulation of PLD1 and PI4KB.	DNAJC13 ZDHHC5 MUC16 RNF213 AP3B1 ADD1 ADD3 CEP350 NUP155 EGFR MPHOSPH9 PRRC2B	7.64e-05	777	140	12	35844135
Pubmed	Characterization of cDNA clones in size-fractionated cDNA libraries from human brain.	CEP350 VPS13D PDE4DIP RERE	7.85e-05	56	140	4	9455484
Pubmed	A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning.	TTF2 SYNRG VPS37A AAK1 DAXX AP3B1 ANKZF1 ADD1 ADD3 CEP350 SMG7 GORASP1 LSM11 MPHOSPH9	8.14e-05	1038	140	14	26673895
Pubmed	An inducible CRISPR/Cas9 screen identifies DTX2 as a transcriptional regulator of human telomerase.	ARHGAP32 ZDHHC5 ADD3 PRR12 NUP155 EGFR	9.35e-05	180	140	6	35198878
Pubmed	Ten-m2 is required for the generation of binocular visual circuits.	FOS EPHB1	9.60e-05	4	140	2	23884953
Pubmed	Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.	EGFR ROS1	9.60e-05	4	140	2	34558414
Pubmed	S/T phosphorylation of DLL1 is required for full ligand activity in vitro but dispensable for DLL1 function in vivo during embryonic patterning and marginal zone B cell development.	UNCX NEUROG1	9.60e-05	4	140	2	24449764
Pubmed	Signaling by ephrinB1 and Eph kinases in platelets promotes Rap1 activation, platelet adhesion, and aggregation via effector pathways that do not require phosphorylation of ephrinB1.	EPHA4 EPHB1	9.60e-05	4	140	2	14576067
Pubmed	Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17.	FOS EGFR	9.60e-05	4	140	2	22772468
Pubmed	Nuclear FGFR2 Interacts with the MLL-AF4 Oncogenic Chimera and Positively Regulates HOXA9 Gene Expression in t(4;11) Leukemia Cells.	KMT2A FGFR2	9.60e-05	4	140	2	33924850
Pubmed	Quetiapine and aripiprazole signal differently to ERK, p90RSK and c-Fos in mouse frontal cortex and striatum: role of the EGF receptor.	FOS EGFR	9.60e-05	4	140	2	24552586
Pubmed	Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta.	FOS SOS2	9.60e-05	4	140	2	9058381
Pubmed	Glycosylation Changes in Serum Proteins Identify Patients with Pancreatic Cancer.	CEP350 LIFR	9.60e-05	4	140	2	28244758
Pubmed	EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2.	EGFR TARBP2	9.60e-05	4	140	2	23636329
Pubmed	beta-adducin (Add2) KO mice show synaptic plasticity, motor coordination and behavioral deficits accompanied by changes in the expression and phosphorylation levels of the alpha- and gamma-adducin subunits.	ADD1 ADD3	9.60e-05	4	140	2	19900187
Pubmed	EGF-responsive neural stem cells are a transient population in the developing mouse spinal cord.	EGFR FGFR2	9.60e-05	4	140	2	11553295
Pubmed	The role of Dicer protein partners in the processing of microRNA precursors.	RBBP6 TARBP2	9.60e-05	4	140	2	22163034
Pubmed	RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy.	ARHGAP32 IRS4 ZDHHC5 KIAA1549 NUP155 SMG7 PRRC2B	9.97e-05	263	140	7	34702444
Pubmed	Endofin is required for HD-PTP and ESCRT-0 interdependent endosomal sorting of ubiquitinated transmembrane cargoes.	SYNRG ARHGAP32 VPS37A EGFR	1.03e-04	60	140	4	34761192
Pubmed	Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer.	RBBP6 SIPA1L3 CEP350 PRR12 SMG7 ZNF592	1.05e-04	184	140	6	32908313
GeneFamily	Sterile alpha motif domain containing	SAMD9 BICC1 EPHA4 EPHB1	8.57e-04	88	87	4	760
GeneFamily	Receptor Tyrosine Kinases\|CD molecules	LMTK2 ROS1 FGFR2	9.35e-04	40	87	3	321
GeneFamily	Fibronectin type III domain containing	MYBPH LIFR ROS1 EPHA4 EPHB1	1.05e-03	160	87	5	555
GeneFamily	Fibronectin type III domain containing\|Sterile alpha motif domain containing\|EPH receptors	EPHA4 EPHB1	2.01e-03	14	87	2	1095
GeneFamily	ATPase phospholipid transporting	ATP8B1 ATP10A	2.31e-03	15	87	2	1210
GeneFamily	Sulfatases	ARSK ARSF	3.33e-03	18	87	2	410
ToppCell	Tracheal-NucSeq\|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations	STARD13 ARHGAP32 DYM ARHGEF28 SIPA1L3 ZNF407 RERE HERC1 TRAPPC9	1.35e-08	199	139	9	94b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCell	renal_medulla_nuclei-Adult_normal_reference\|renal_medulla_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group	STARD13 FOS AAK1 SYBU LIFR PDE4DIP RERE TRAPPC9	1.53e-07	190	139	8	f1363f7806cfc4f14fbc1b0e8dac2de813a88eee
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ARHGEF28 OXR1 SIPA1L3 TOM1L1 LAMA1 FGFR2 RERE BICC1	1.94e-07	196	139	8	eea66711a16134f86e6c533a5a837ff2e0d7ca7f
ToppCell	human_hepatoblastoma-Tumor_cells-T5\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	SIPA1L3 VCAN PIP5K1B FGFR2 RERE STRA6 UNC79	2.13e-06	188	139	7	b070a0667f1ee9b825b267b6c389b7c42fc436f9
ToppCell	RV-10._Endothelium_II\|World / Chamber and Cluster_Paper	OXR1 ATP8B1 ATP10A ADD1 LIFR ART4 EPHA4	2.54e-06	193	139	7	2531266bc57339d4e2b22a88817008e32b8c1598
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ARHGEF28 OXR1 TOM1L1 LAMA1 FGFR2 SPAG17 BICC1	2.62e-06	194	139	7	93c68c31e39fa44c1d05d7d4997f4f086da4e738
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	ARHGEF28 OXR1 SIPA1L3 TOM1L1 FGFR2 RERE BICC1	2.72e-06	195	139	7	6477e6e7be5bd8eb99119a12ae16334ccddecd43
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ARHGEF28 OXR1 SIPA1L3 TOM1L1 LAMA1 FGFR2 BICC1	2.81e-06	196	139	7	6ce74aa3f0ce3ca284b67e5a4660ffd2cc9611e0
ToppCell	Control-Stromal-Fibroblast\|Stromal / Disease state, Lineage and Cell class	SH3TC2 FOS NOX4 ZFPM2 ADD3 VCAN BICC1	2.90e-06	197	139	7	64cc5f61c88e9560b0f8f6f3151255dffb5c3d66
ToppCell	Parenchymal-NucSeq\|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations	STARD13 ARHGAP32 SIPA1L3 ZNF407 EGFR RERE TRAPPC9	3.00e-06	198	139	7	1996373bdccc55aac347d349bd22f6aad6d0c668
ToppCell	3'_v3-lymph-node_spleen-Lymphocytic_T_CD4-T_CD4/CD8\|lymph-node_spleen / Manually curated celltypes from each tissue	AAK1 AKNA RNF213 ZNF407 JMY HERC1	1.63e-05	171	139	6	2e9a20f8980b78325c52065a9c14ab3656267c05
ToppCell	COVID-19-kidney-vSMC/Pericyte\|COVID-19 / Disease (COVID-19 only), tissue and cell type	NBEAL1 TRPC4 ITGA8 ATP8B1 ATP10A PIP5K1B	2.11e-05	179	139	6	111b1084f73306bdeffaaf240e7dbb4f5bf33de1
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	OXR1 LAMA1 CCNP PIP5K1B BICC1 EPHA4	2.25e-05	181	139	6	9d782ba5cf5a172cb4f447763fc50e5b13ef7dd9
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_3\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	UNCX LAMA1 CCNP PIP5K1B BICC1 EPHA4	2.32e-05	182	139	6	eb138aa1dca9373f1586600f258df06dcf56d81f
ToppCell	RA-13._Vascular_Smooth_Muscle\|RA / Chamber and Cluster_Paper	ARHGEF28 NBEAL1 TRPC4 ITGA8 ATP10A PIP5K1B	2.39e-05	183	139	6	818fd886e0188091310825f9145fa53328f2c979
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_1\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	UNCX OXR1 CCNP FGFR2 BICC1 EPHA4	2.39e-05	183	139	6	cfae90c309622b5d499e62a3a8a8b9746478d28d
ToppCell	pdx\|World / Sample and Cell Type and Tumor Cluster (all cells)	SIPA1L3 TNRC18 PIP5K1B MPHOSPH9 RERE TRAPPC9	2.62e-05	186	139	6	de8e538c8767d41b8a52f5e58ba1affd4e7244c4
ToppCell	pdx-Tumor_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	SIPA1L3 TNRC18 PIP5K1B MPHOSPH9 RERE TRAPPC9	2.62e-05	186	139	6	0b88a87158a9ca8de3bf40a4ff1687150707a5f0
ToppCell	TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-1\|TCGA-Pancreas / Sample_Type by Project: Shred V9	OXR1 NBEAL1 RBBP6 ADD3 CEP350 VPS13D	2.62e-05	186	139	6	03db813598b67b1e08f759758a1c2023396921fa
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TRPC4 ITGA8 KIAA1549 ATP10A SSC5D PIP5K1B	2.70e-05	187	139	6	15d6e158562d7d85af3ceaf955439b379c8fce81
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TRPC4 ITGA8 KIAA1549 ATP10A SSC5D PIP5K1B	2.70e-05	187	139	6	f62074b631fd45ad299c69d71b09267b04d656ee
ToppCell	TCGA-Breast-Primary_Tumor-Breast_Carcinoma-Infiltrating_Ductal_Carcinoma-6\|TCGA-Breast / Sample_Type by Project: Shred V9	NOX4 SLC40A1 ZFPM2 SSC5D VCAN BICC1	2.70e-05	187	139	6	a96495803ba13fcfadd1d83b3cf5774f3fed0a20
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical-aged\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TRPC4 ITGA8 KIAA1549 ATP10A SSC5D PIP5K1B	2.78e-05	188	139	6	32f22a4d8cb98fd8b8fa0fbf28ef9266d711d081
ToppCell	LA-13._Vascular_Smooth_Muscle\|World / Chamber and Cluster_Paper	ARHGEF28 NBEAL1 TRPC4 ITGA8 ATP8B1 ATP10A	2.87e-05	189	139	6	6b3e88751b95fc2173f2c3d5061ed632d0c5f01c
ToppCell	RA-10._Endothelium_II\|World / Chamber and Cluster_Paper	OXR1 FOS ITGA8 ATP8B1 ART4 VCAN	2.87e-05	189	139	6	75c248b9de5e2fb7a0baa8cdbab516e575cc4394
ToppCell	COPD-Endothelial-VE_Arterial\|Endothelial / Disease state, Lineage and Cell class	SH3TC2 AAK1 ADD1 LIFR EGFR EPHA4	3.04e-05	191	139	6	ef16ad1c1cd2c0c0377957398c98775b62a81754
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	ITGA8 SLC40A1 ZFPM2 LIFR BICC1 EPHB1	3.04e-05	191	139	6	fa380a8752de158974b2ae5e741573439719cc0d
ToppCell	facs-Aorta-Heart-3m-Mesenchymal\|Aorta / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADD3 EGFR VCAN FGFR2 BICC1 PLXNB1	3.13e-05	192	139	6	0dc1f46e40346ed0b286e53b106a812441575100
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ARHGEF28 OXR1 TOM1L1 FGFR2 BICC1 PLXNB1	3.32e-05	194	139	6	5eaaa81f4b2535f983c424aaef00077089526a5c
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	ITGA8 SLC40A1 ZFPM2 LIFR VCAN BICC1	3.32e-05	194	139	6	8c37bedb23285735ff3828db3889897fada8c95d
ToppCell	IPF-Endothelial-VE_Venous\|Endothelial / Disease state, Lineage and Cell class	SH3TC2 MASP1 FOS ATP8B1 LIFR NFE2L1	3.32e-05	194	139	6	e8a9005963704286bcc50785bda8d7d63ec001b1
ToppCell	LA-02._Fibroblast_II\|LA / Chamber and Cluster_Paper	NOX4 ZFPM2 ADD3 EGFR VCAN BICC1	3.32e-05	194	139	6	234d1494c114cce77c619708bbcd8d5ce805f19b
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TRPC4 ITGA8 ATP10A ZFPM2 ART4 VCAN	3.42e-05	195	139	6	49c99553629cdd83ee56a2e508d5bc8d34b8507b
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TRPC4 ITGA8 ATP10A ZFPM2 ART4 VCAN	3.42e-05	195	139	6	dd281a249854800f737dc22e0f375f66dfb5cf5f
ToppCell	Bronchial-NucSeq\|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations	STARD13 SIPA1L3 ZNF407 PIP5K1B RERE TRAPPC9	3.52e-05	196	139	6	ab53c742866945545a92e2e61850d63c80d9a2a6
ToppCell	systemic_lupus_erythematosus-flare-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-female\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	MAGEA4 DIPK1C SAMD9 AAK1 AKNA RNF213	3.62e-05	197	139	6	2e9677b4b9a7c88db16416e5f114a2031ec3bc24
ToppCell	Brain_organoid-organoid_Paulsen_bioRxiv-6_mon\|organoid_Paulsen_bioRxiv / Sample Type, Dataset, Time_group, and Cell type.	DIPK1C FOS ADD3 EGFR KCNJ10 HADHB	3.62e-05	197	139	6	58b957efd006f43c2fe55071d5c6d06c2e367e72
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	ITGA8 SLC40A1 ADD3 LIFR VCAN BICC1	3.62e-05	197	139	6	11a4c417f035e554431a8f03be13b5eefa3530c0
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	ITGA8 SLC40A1 ZFPM2 LIFR VCAN BICC1	3.72e-05	198	139	6	17dc055e2a289496d9c5cdbf3297bdf906dc6d22
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	LAMA1 ITGA8 SLC40A1 LIFR VCAN BICC1	3.83e-05	199	139	6	a7dd94b172c973a131a6792f8ccd9bfe44d984ac
ToppCell	kidney_cells-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	OXR1 VPS13D VCAN KMT2A FGFR2 PLXNB1	3.83e-05	199	139	6	174f6013af6eafa577f84205a62927f2b367fda3
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-4M-Radial_glial\|Organoid-4M / Sample Type, Dataset, Time_group, and Cell type.	DIPK1C MASP1 FOS LIFR KCNJ10 HADHB	3.93e-05	200	139	6	ed4a41cb6782541d8fc928aaa12cf03bc1c630a2
ToppCell	Tracheal-NucSeq-Epithelial-Epi_submucosal-gland\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	ARHGAP32 ARHGEF28 TOM1L1 MUC16 ATP8B1 PIP5K1B	3.93e-05	200	139	6	0eb9ad8c0373bcc62029ec21c590ed03aaacd039
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-4M-Radial_glial-gliogenic/outer_RGCs_and_astrocytes\|Organoid-4M / Sample Type, Dataset, Time_group, and Cell type.	DIPK1C MASP1 FOS LIFR KCNJ10 HADHB	3.93e-05	200	139	6	792fef1f3e47ce5c131fedfad55075fc254aeead
ToppCell	droplet-Lung-immune-endo-depleted-3m-Myeloid-neutrophil\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	STARD13 ARHGEF28 SLC22A15 CASP9 SLC40A1	6.13e-05	133	139	5	f6e9a1301a3379847b215303a9b0c028841e2cc0
ToppCell	droplet-Lung-immune-endo-depleted-3m-Myeloid-Neutrophil\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	STARD13 ARHGEF28 SLC22A15 CASP9 SLC40A1	6.13e-05	133	139	5	292ecfcadbaf15e0d34a3ab9bf511ab1065888bd
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW09-Macroglial-Astrocyte\|GW09 / Sample Type, Dataset, Time_group, and Cell type.	LAMA1 CASP9 ZDBF2 BICC1 RABGGTA	8.36e-05	142	139	5	85e573616e54d41391b4ad8c3d38e4ca92112673
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-L5_IT-L5_IT_VISp_Col27a1\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	ITGA8 TTC7A RP1L1 LSM11 EPHB1	1.22e-04	154	139	5	d22902d2922784583f7016453768ed05b14b965e
ToppCell	356C-Lymphocytic-NK_cells-NK_cell_A2\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	TRIOBP KIAA1549 TTC7A ART4 KCNH2	1.51e-04	161	139	5	8ec923c230a7a3cce5edf2a736b3a00d607c698a
ToppCell	LV-13._Vascular_Smooth_Muscle\|World / Chamber and Cluster_Paper	KLF8 NBEAL1 ITGA8 ATP10A PIP5K1B	1.69e-04	165	139	5	f37fd95adc95d7753cf6e55ae819976513c7ec77
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TRPC4 ITGA8 ATP10A ART4 PIP5K1B	1.79e-04	167	139	5	b4ef07117d14da3d5fbced949e4dfcb01c392295
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TRPC4 ITGA8 ATP10A ART4 PIP5K1B	1.79e-04	167	139	5	94fc7df7ca55cd722a8dbd153201a29891217473
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TRPC4 ITGA8 ATP10A ART4 PIP5K1B	1.79e-04	167	139	5	eff3723fe60755272eca237459165e436e919ece
ToppCell	Control\|World / group, cell type (main and fine annotations)	ARHGEF28 FOS EGFR PIP5K1B ROS1	1.84e-04	168	139	5	a3511faf2cd2c2b9c8363c8b99da3f3609c43ed6
ToppCell	P28-Epithelial-airway_epithelial_cell-ciliated_cell_of_airway\|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	KLF8 ARHGEF28 ITGA8 PKMYT1 TNRC18	1.84e-04	168	139	5	8c8dbdbc7053f34e4ca0c5067af502fbea109fc1
ToppCell	facs-Trachea-3m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l6-17\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TRPC4 ZDBF2 KCNH2 PIP5K1B UNC79	1.94e-04	170	139	5	941d637cf76918ee4b0a1833abd1a42593cb8b1a
ToppCell	severe_COVID-19-Neutrophil\|severe_COVID-19 / disease group, cell group and cell class (v2)	SAMD9 FOS IER3 UNC79 EPHB1	2.05e-04	172	139	5	8f4bcb9b2bbf8b4333f673d8ad6bb88dfda4792a
ToppCell	RSV-Healthy-1\|Healthy / Virus stimulation, Condition and Cluster	SAMD9 RNF213 ATP8B1 ATP10A PLXNB1	2.22e-04	175	139	5	ff3a27f512a3a710ebc863b7b75cce8167d5440b
ToppCell	RSV-Healthy-1\|RSV / Virus stimulation, Condition and Cluster	SAMD9 RNF213 ATP8B1 ATP10A PLXNB1	2.22e-04	175	139	5	ca52b99b03535a5b3a2751d6981708dc5b255b91
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	EEF1AKMT4-ECE2 ITGA8 ATP10A ZFPM2 PIP5K1B	2.22e-04	175	139	5	d52794426f2703a80e91ae0a8ff2d8e0ce4aa4a8
ToppCell	Adult-Epithelial-lung_neuroendocrine_cell_(PNEC)\|Adult / Lineage, Cell type, age group and donor	FRMPD1 KCNH2 FMN2 UNC79 EPHB1	2.22e-04	175	139	5	4db1a3c284488b3f6de7568363f176d74e2a4587
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	EEF1AKMT4-ECE2 ITGA8 ATP10A ZFPM2 PIP5K1B	2.22e-04	175	139	5	454f03e6109d65f5db08dbb41ecc19ffb6bbc4e0
ToppCell	Adult-Epithelial-lung_neuroendocrine_cell_(PNEC)-D231\|Adult / Lineage, Cell type, age group and donor	FRMPD1 KCNH2 FMN2 UNC79 EPHB1	2.22e-04	175	139	5	8d9f44a2633b71fb4d2b4a7d9530f954e07c4a18
ToppCell	kidney_cells-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_2\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MASP1 CCNP EGFR SPAG17 BICC1	2.28e-04	176	139	5	33323c97afe509147956b8df9f92ca6b0537e604
ToppCell	3'-Distal_airway-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophages-Alveolar_macrophages_L.1.0.3.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	TTC7A SSC5D TTC7B RP1L1 SOS2	2.28e-04	176	139	5	76fdf211bce101e83a27d822cb399487bd107027
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L2-5_VIP_TOX2\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ITGA8 NOX4 ARSF EGFR VCAN	2.34e-04	177	139	5	85e270b4a0b0da77ffe5987a099e827c02a4adf3
ToppCell	5'-Parenchyma_lung-Immune_Myeloid-Myeloid_macrophage-elicited_macrophage-Monocyte-derived_macrophage-Monocyte-derived_macrophage_L.1.2.3.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	JMY PKMYT1 IER3 KCNJ10 MPHOSPH9	2.34e-04	177	139	5	f28243b51be104cb3adcde63f03fc2206ed3121e
ToppCell	facs-Trachea-24m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l6-17\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ITGA8 LMTK2 ZDBF2 AASDH SH2D7	2.34e-04	177	139	5	8abdf1d970b2f15e17e185f3e612dd5065c88757
ToppCell	TCGA-Brain-Primary_Tumor-Low_Grade_Glioma\|TCGA-Brain / Sample_Type by Project: Shred V9	JMY VPS13D KCNJ10 KMT2A HERC1	2.34e-04	177	139	5	e8ab340b20cd41554c3841fe980e078e878af35f
ToppCell	saliva-Severe-critical_progression_d12-22_with-steroid-Myeloid-Monocytic-Nonclassical_Monocyte-Mono_c5-CD16\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	DYM COG7 EIF2D ARSF	2.42e-04	97	139	4	332b4daf5106872dd891d9f9b5a891192d5d9aa8
ToppCell	droplet-Heart-4Chambers-21m-Mesenchymal-nan\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ITGA8 KIAA1549 ZFPM2 LONRF3 UNC79	2.46e-04	179	139	5	b44e2d53b82c3c141bfc6539054b19708200a0d9
ToppCell	facs-Lung-EPCAM-3m-Epithelial-Alveolar_Epithelial_Type_1\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARHGEF28 TOM1L1 SYBU GORASP1 GPAT2	2.46e-04	179	139	5	88dbec952507d84b85b08165eec80df99ed1e736
ToppCell	facs-Lung-EPCAM-3m-Epithelial-type_I_pneumocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARHGEF28 TOM1L1 SYBU GORASP1 GPAT2	2.46e-04	179	139	5	daf8189a22786171e2b629261cf720736aa4ebdb
ToppCell	Adult-Epithelial-lung_goblet_cell\|Adult / Lineage, Cell type, age group and donor	ARHGEF28 MUC16 SYBU FGFR2 STRA6	2.46e-04	179	139	5	1fc1f252ca943a2f649d1e627f56acbf15f8e058
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L2-6_VIP_VIP\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ARHGEF28 ITGA8 NOX4 EGFR VCAN	2.46e-04	179	139	5	01302505816f272243659e20d751b61a198a2fc0
ToppCell	390C-Fibroblasts-Fibroblast-G\|390C / Donor, Lineage, Cell class and subclass (all cells)	MASP1 TRPC4 ITGA8 SLC40A1 VCAN	2.53e-04	180	139	5	137fc14859c89e1ecd98bee388bb58c04b835847
ToppCell	390C-Fibroblasts-Fibroblast-G-\|390C / Donor, Lineage, Cell class and subclass (all cells)	MASP1 TRPC4 ITGA8 SLC40A1 VCAN	2.53e-04	180	139	5	cd6790de050151fedfa2c5ea6ad58b72665414b2
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_2\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	SH3TC2 OXR1 ATP10A EGFR BICC1	2.66e-04	182	139	5	5e1b316599436740f1b30875f0ebd33c3edfb2b6
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L1-6_VIP_RGS16\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ARHGEF28 TRPC4 ARSF EGFR VCAN	2.66e-04	182	139	5	724c33ad2fb525cbcfa5efa3362675eb42a5636d
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	LIFR EGFR PIP5K1B ROS1 FGFR2	2.73e-04	183	139	5	6847c1252d6bb105524f812658112517fd351eab
ToppCell	Calu_3-infected\|Calu_3 / Cell line, Condition and Strain	SAMD9 RBBP6 RNF213 CEP350 IER3	2.73e-04	183	139	5	8f7f5000645f24f20a8d7700c4df1f8953a1780b
ToppCell	Epithelial-lung_goblet_cell\|World / Lineage, Cell type, age group and donor	ARHGEF28 MUC16 ATP8B1 SYBU FGFR2	2.73e-04	183	139	5	940cbe298e9c53b5622af09264586ed823d3141f
ToppCell	IPF-Epithelial-Mesothelial\|World / Disease state, Lineage and Cell class	SH3TC2 MUC16 ZFPM2 EGFR BICC1	2.73e-04	183	139	5	7df20e3172a1220ff427f30181f4f0c3b7fe2d42
ToppCell	RA-13._Vascular_Smooth_Muscle\|World / Chamber and Cluster_Paper	ARHGEF28 NBEAL1 TRPC4 ITGA8 ATP10A	2.73e-04	183	139	5	cae2ee08f985a6f005b4b8e959e465350315156a
ToppCell	normal_Lung-Fibroblasts-Myofibroblasts\|normal_Lung / Location, Cell class and cell subclass	DIPK1C ITGA8 SSC5D ZNF469 STRA6	2.80e-04	184	139	5	0b336489c10e8c3c957795dd845454f03404382b
ToppCell	droplet-Heart-HEART-1m-Hematologic-red_blood_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SIPA1L3 ZNF280C VPS13D EPHB1	2.82e-04	101	139	4	6c4524be89cf3eb06769c2963dcded3da1e71ca0
ToppCell	Adult-Mesenchymal-matrix_fibroblast_2_cell-D231\|Adult / Lineage, Cell type, age group and donor	MASP1 NOX4 ZFPM2 SSC5D BICC1	2.87e-04	185	139	5	fb6bd7e849ecf4ed9cd9c4e2a946a2d12d62f804
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_2\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	SH3TC2 OXR1 LIFR EGFR BICC1	2.94e-04	186	139	5	5c4ffe4e4d5536ae9f8794277fe032c693e7dd56
ToppCell	Dendritic_Cells-Donor_01\|World / lung cells shred on cell class, cell subclass, sample id	DIPK1C FOS PKMYT1 IER3 VCAN	2.94e-04	186	139	5	1d52912bd17e232cf39b2423a4d93585c164ba34
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	OXR1 SIPA1L3 NOX4 FGFR2 BICC1	2.94e-04	186	139	5	b87acc80b7baa41681e4ed11d5537b9fbf5832f5
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ARHGAP32 ARHGEF28 EGFR ROS1 FGFR2	2.94e-04	186	139	5	e83718fabb057100835d3357df407f283d23fe16
ToppCell	COVID-19-kidney-Fibroblast-1\|COVID-19 / Disease (COVID-19 only), tissue and cell type	TRPC4 ZDBF2 MTRNR2L6 ART4 BICC1	3.01e-04	187	139	5	76bfe8c42430a230a8bdf299575c444fb7780f24
ToppCell	Primary_Visual_cortex_(V1C)-Non-neuronal-Macroglial\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SH3TC2 VCAN KCNJ10 FGFR2 PLXNB1	3.01e-04	187	139	5	97e520705491c8f52a32025311a9fa7b9176979a
ToppCell	COPD-Epithelial-ATII\|Epithelial / Disease state, Lineage and Cell class	STARD13 PIP5K1B ROS1 LONRF3 EPHA4	3.01e-04	187	139	5	030af361f8bdcd0aff4ec1922702833325cf74d8
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_1\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	UNCX CCNP EGFR VCAN BICC1	3.01e-04	187	139	5	9225caf66e06ebe57e90d677122acb6498607f36
ToppCell	Somatosensory_Cortex_(S1)-Non-neuronal-Macroglial-Oligo\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SH3TC2 VCAN KCNJ10 FGFR2 PLXNB1	3.09e-04	188	139	5	60242c29c7f16c94a84685d3bc4ed93a66e70152
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	TRPC4 ITGA8 ATP10A ZFPM2 PIP5K1B	3.09e-04	188	139	5	b2d68a32314e9b099ed74d974079ad96359d1ae3
ToppCell	-Unknown-Endothelial-Myofibroblast\| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ZDBF2 ZFPM2 EIF2D KMT2A BICC1	3.09e-04	188	139	5	6468fa95ad0395395301115286f2d8c0df5d3882
ToppCell	-Unknown-Endothelial\| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ZDBF2 ZFPM2 EIF2D KMT2A BICC1	3.09e-04	188	139	5	7a81ac5c79c3eb26639b52d2b9fd5e7ef9798fd6
ToppCell	LA-13._Vascular_Smooth_Muscle\|LA / Chamber and Cluster_Paper	ARHGEF28 NBEAL1 TRPC4 ITGA8 ATP10A	3.09e-04	188	139	5	34e1b074a3995aa46ab194eb45115d76d1a5514d
Drug	imatinib	TOM1L1 LAMA1 CASP9 ADD3 PKMYT1 LIFR EGFR PDE4DIP ROS1 FGFR2 RERE EPHA4 EPHB1	2.08e-06	430	137	13	CID000005291
Drug	methyl ethyl ketone	MASP1 FOS TOM1L1 LAMA1 CASP9 ART4 EGFR IER3 GORASP1 FGFR2 HADHB SPAG17 EPHA4 EPHB1 SOS2	2.65e-06	587	137	15	CID000006569
Drug	Apomorphine hydrochloride hemihydrate [41372-20-7]; Down 200; 6.4uM; HL60; HG-U133A	AAK1 MAST2 ADD1 VPS13D SMG7 BAZ2A MPHOSPH9 TRAPPC9 SOS2	3.00e-06	196	137	9	2005_DN
Drug	2-propylpentanoic acid; Down 200; 50uM; HL60; HT_HG-U133A	ARHGAP32 FRMPD1 AP3B1 SBNO2 DZANK1 FGFR2 RERE LONRF3 SOS2	3.39e-06	199	137	9	2682_DN
Drug	2-Chloropyrazine [14508-49-7]; Down 200; 35uM; HL60; HT_HG-U133A	ARHGAP32 SIPA1L3 TUT1 MAST2 SBNO2 VPS13D SMG7 JHY SOS2	3.39e-06	199	137	9	6148_DN
Drug	17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A	RBBP6 PPRC1 SIPA1L3 TRIOBP ANKZF1 SMG7 ZNF592 BAZ2A	2.18e-05	192	137	8	6986_DN
Drug	Amprolium hydrochloride [137-88-2]; Down 200; 12.6uM; PC3; HT_HG-U133A	FRMPD1 AAK1 TUT1 SBNO2 OSBP2 FGFR2 TRAPPC9 PLXNB1	2.27e-05	193	137	8	4241_DN
Drug	(S)-(-)-Cycloserine [339-72-0]; Down 200; 39.2uM; PC3; HT_HG-U133A	SH3TC2 DNAJC13 PPRC1 MAST2 BAZ2A KMT2A BICRAL EPHA4	2.35e-05	194	137	8	4524_DN
Drug	Pergolide mesylate [66104-23-2]; Up 200; 9.8uM; MCF7; HT_HG-U133A	AAK1 ZNF407 ANKZF1 CEP350 KMT2A BICRAL FGFR2 RERE	2.44e-05	195	137	8	7434_UP
Drug	Isoconazole [27523-40-6]; Down 200; 9.6uM; PC3; HT_HG-U133A	STARD13 TRIOBP ANKZF1 SMG7 KMT2A MPHOSPH9 HERC1 LONRF3	2.53e-05	196	137	8	2056_DN
Drug	Suxibuzone [27470-51-5]; Down 200; 9.2uM; PC3; HT_HG-U133A	SAMD9 MAST2 VPS13D SMG7 BAZ2A KMT2A LONRF3 PRRC2B	2.53e-05	196	137	8	5806_DN
Drug	Meptazinol hydrochloride [59263-76-2]; Down 200; 14.8uM; MCF7; HT_HG-U133A	ARHGAP32 SAMD9 CASP9 MAST2 ANKZF1 VPS13D SMG7 BAZ2A	2.63e-05	197	137	8	4774_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	STARD13 AAK1 TRIOBP CASP9 ANKZF1 VPS13D EGFR BAZ2A	2.63e-05	197	137	8	6222_DN
Drug	fluphenazine dihydrochloride; Up 200; 10uM; PC3; HT_HG-U133A	FOS TUT1 MAST2 ANKZF1 OSBP2 BICC1 EPHA4 EPHB1	2.63e-05	197	137	8	1237_UP
Drug	Acenocoumarol [152-72-7]; Up 200; 11.4uM; MCF7; HT_HG-U133A	SIPA1L3 SYBU DZANK1 SMG7 KMT2A FGFR2 JHY SOS2	2.72e-05	198	137	8	7232_UP
Drug	Glycopyrrolate [596-51-0]; Down 200; 10uM; MCF7; HT_HG-U133A	MAST2 SBNO2 SMG7 BAZ2A KCNH2 PDE4DIP RERE TRAPPC9	2.72e-05	198	137	8	3427_DN
Drug	Sulfisoxazole [127-69-5]; Down 200; 15uM; PC3; HT_HG-U133A	ARHGAP32 FRMPD1 VPS13D SMG7 VCAN RERE JHY SOS2	2.72e-05	198	137	8	4661_DN
Drug	Vinpocetine [42971-09-5]; Down 200; 11.4uM; PC3; HT_HG-U133A	SIPA1L3 TUT1 VPS13D ZNF592 BAZ2A MPHOSPH9 RABGGTA PRRC2B	2.82e-05	199	137	8	5859_DN
Drug	Meropenem [96036-03-2]; Down 200; 10.4uM; PC3; HT_HG-U133A	SAMD9 ATP8B1 AP3B1 MAST2 ANKZF1 ADD1 CEP350 SMG7	2.82e-05	199	137	8	5824_DN
Drug	sodium 4-phenylbutyrate; Down 200; 1000uM; MCF7; HG-U133A	ARHGAP32 CCNP TUT1 SBNO2 VPS13D RERE PRRC2B EPHA4	2.82e-05	199	137	8	408_DN
Drug	Acyclovir [59277-89-3]; Down 200; 17.8uM; PC3; HG-U133A	RBBP6 SIPA1L3 CCNP AAK1 ADD1 KMT2A MPHOSPH9 HERC1	2.82e-05	199	137	8	1960_DN
Drug	Fenoprofen calcium salt dihydrate [53746-45-5]; Up 200; 7.2uM; PC3; HT_HG-U133A	IRS4 CCNP ZNF407 RNF17 PDE4DIP VRTN TRAPPC9 EPHB1	2.93e-05	200	137	8	3714_UP
Drug	trioctyltrimellitate	ART4 POLK	3.59e-05	2	137	2	CID000006960
Drug	AC1NST48	SYNRG DNAJC13 DYM COG7 CASP9 SYBU AP3B1 ART4 EGFR KCNH2 GORASP1 VCAN HERC1	6.34e-05	594	137	13	CID005315496
Drug	silicon;titanium	ARHGAP32 DYM	1.07e-04	3	137	2	CID006336553
Drug	FD137 nitrosourea	FOS EGFR	1.07e-04	3	137	2	ctd:C471268
Drug	DETA/NO	FOS CASP9 NOX4 NEUROG1 GORASP1	1.23e-04	80	137	5	CID000004518
Drug	17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A	ZNF407 RNF17 ATP10A KCNH2 PDE4DIP FGFR2 PLXNB1	1.51e-04	189	137	7	5586_UP
Drug	Ketanserin tartrate hydrate [83846-83-7]; Down 200; 7uM; PC3; HT_HG-U133A	CEP350 SMG7 EGFR BAZ2A VCAN PDE4DIP KMT2A	1.51e-04	189	137	7	6649_DN
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A	STARD13 SIPA1L3 LMTK2 ADD3 EGFR PDE4DIP FGFR2	1.56e-04	190	137	7	2375_UP
Drug	Butamben [94-25-7]; Down 200; 20.6uM; PC3; HT_HG-U133A	SH3TC2 ARHGEF28 EGFR PDE4DIP BICC1 PRRC2B SOS2	1.61e-04	191	137	7	5792_DN
Drug	naphtho(1,2-b)furan-4,5-dione	FOS CASP9 EGFR	1.63e-04	18	137	3	ctd:C073873
Drug	Isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride; Down 200; 16.4uM; PC3; HT_HG-U133A	SAMD9 FRMPD1 TUT1 MAST2 VCAN FGFR2 PLXNB1	1.71e-04	193	137	7	4226_DN
Drug	Metanephrine hydrochloride DL [881-95-8]; Down 200; 17.2uM; PC3; HT_HG-U133A	SIPA1L3 SBNO2 SMG7 EGFR PDE4DIP PLXNB1 SOS2	1.71e-04	193	137	7	6734_DN
Drug	Diphenidol hydrochloride [3254-89-5]; Down 200; 11.6uM; MCF7; HT_HG-U133A	SYNRG TRIOBP ANKZF1 VPS13D BAZ2A FGFR2 SOS2	1.71e-04	193	137	7	7447_DN
Drug	Dipyrone [5907-38-0]; Down 200; 12uM; MCF7; HT_HG-U133A	SIPA1L3 MAST2 CEP350 PDE4DIP FGFR2 PLXNB1 SOS2	1.83e-04	195	137	7	3835_DN
Drug	Perphenazine [58-39-9]; Down 200; 10uM; PC3; HG-U133A	RBBP6 PPRC1 SIPA1L3 CCNP ATP8B1 ZNF592 BAZ2A	1.83e-04	195	137	7	1956_DN
Drug	Calycanthine [595-05-1]; Down 200; 11.6uM; PC3; HT_HG-U133A	SIPA1L3 TRIOBP VPS13D BAZ2A KCNH2 VCAN EPHA4	1.83e-04	195	137	7	5744_DN
Drug	Ethopropazine hydrochloride [1094-08-2]; Up 200; 11.4uM; HL60; HT_HG-U133A	ZNF407 ART4 BAZ2A PDE4DIP STRA6 PLXNB1 EPHB1	1.83e-04	195	137	7	3038_UP
Drug	Pyrantel tartrate [33401-94-4]; Up 200; 11.2uM; MCF7; HT_HG-U133A	SIPA1L3 ITGA8 KMT2A OSBP2 FGFR2 RERE SOS2	1.83e-04	195	137	7	2260_UP
Drug	Trimethobenzamide hydrochloride [554-92-7]; Down 200; 9.4uM; PC3; HT_HG-U133A	ZNF407 VPS13D SMG7 BAZ2A FGFR2 BICC1 PLXNB1	1.89e-04	196	137	7	4100_DN
Drug	Prostaglandin E1; Down 200; 10uM; PC3; HT_HG-U133A	SH3TC2 SAMD9 TRIOBP AP3B1 PKMYT1 CEP350 BAZ2A	1.89e-04	196	137	7	6571_DN
Drug	Sulfadoxine [2447-57-6]; Up 200; 12.8uM; PC3; HT_HG-U133A	SAMD9 ATP10A LIFR VCAN PDE4DIP EPHB1 SOS2	1.89e-04	196	137	7	5852_UP
Drug	Mifepristone [84371-65-3]; Down 200; 9.4uM; PC3; HT_HG-U133A	STARD13 ARHGAP32 ARHGEF28 VPS13D VCAN PRRC2B JHY	1.89e-04	196	137	7	5827_DN
Drug	Seneciphylline [480-81-9]; Down 200; 12uM; PC3; HT_HG-U133A	FRMPD1 SBNO2 SMG7 OSBP2 FGFR2 RERE PLXNB1	1.89e-04	196	137	7	4238_DN
Drug	Corynanthine hydrochloride [66634-44-4]; Down 200; 10.2uM; PC3; HT_HG-U133A	TUT1 SBNO2 VCAN FGFR2 RERE PLXNB1 JHY	1.89e-04	196	137	7	4227_DN
Drug	Mebhydroline 1,5-naphtalenedisulfonate [6153-33-9]; Up 200; 4.8uM; HL60; HT_HG-U133A	MAST2 ADD1 VPS13D SMG7 VCAN BICRAL SOS2	1.89e-04	196	137	7	1333_UP
Drug	Hydrocotarnine hydrobromide [5985-00-2]; Down 200; 13.2uM; MCF7; HT_HG-U133A	SYNRG TRIOBP VPS13D KCNH2 PDE4DIP TRAPPC9 SOS2	1.95e-04	197	137	7	2765_DN
Drug	arachidonic acid sodium salt; Down 200; 10uM; MCF7; HG-U133A	SYNRG MASP1 IRS4 AP3B1 VPS13D BAZ2A KMT2A	1.95e-04	197	137	7	441_DN
Drug	Chloroquine diphosphate [50-63-5]; Down 200; 7.8uM; MCF7; HT_HG-U133A	SYBU ANKZF1 ADD1 SMG7 FGFR2 TRAPPC9 SOS2	1.95e-04	197	137	7	7012_DN
Drug	Esculin Hydrate [531-75-9]; Up 200; 11.8uM; PC3; HT_HG-U133A	SBNO2 VPS13D EGFR BAZ2A PDE4DIP RABGGTA SOS2	1.95e-04	197	137	7	6310_UP
Drug	CGX 0596987; Down 200; 20uM; PC3; HT_HG-U133A	SIPA1L3 ATP10A SMG7 EGFR PDE4DIP PIP5K1B SOS2	1.95e-04	197	137	7	6369_DN
Drug	3-nitropropionic acid; Down 200; 10uM; PC3; HT_HG-U133A	ATP10A SMG7 EGFR PDE4DIP KMT2A PIP5K1B SOS2	1.95e-04	197	137	7	6372_DN
Drug	Nimesulide [51803-78-2]; Down 200; 13uM; HL60; HG-U133A	ATP8B1 MAST2 VPS13D SMG7 NFE2L1 MPHOSPH9 PRRC2B	2.01e-04	198	137	7	1428_DN
Drug	rofecoxib; Down 200; 10uM; MCF7; HG-U133A	CASP9 ATP8B1 MAST2 EGFR BAZ2A FGFR2 EPHB1	2.01e-04	198	137	7	251_DN
Drug	haloperidol; Down 200; 10uM; MCF7; HT_HG-U133A_EA	AAK1 TRIOBP ATP8B1 ADD3 SMG7 BAZ2A TRAPPC9	2.01e-04	198	137	7	1082_DN
Drug	Theobromine [83-67-0]; Down 200; 22.2uM; HL60; HT_HG-U133A	SIPA1L3 TRPC4 ZNF407 SBNO2 PDE4DIP OSBP2 FGFR2	2.01e-04	198	137	7	2995_DN
Drug	Meclozine dihydrochloride [1104-22-9]; Up 200; 8.6uM; HL60; HT_HG-U133A	SIPA1L3 ZFPM2 VPS13D SMG7 PDE4DIP FGFR2 EPHB1	2.01e-04	198	137	7	2424_UP
Drug	Nafcillin sodium salt monohydrate [7177-50-6]; Up 200; 8.8uM; MCF7; HT_HG-U133A	FRMPD1 VPS13D VCAN MPHOSPH9 RERE EPHB1 SOS2	2.01e-04	198	137	7	4103_UP
Drug	Reserpine [50-55-5]; Down 200; 6.6uM; PC3; HT_HG-U133A	FRMPD1 TUT1 EGFR VCAN FGFR2 RERE SOS2	2.01e-04	198	137	7	4203_DN
Drug	Sertaconazole nitrate [99592-39-9]; Up 200; 8uM; MCF7; HT_HG-U133A	SAMD9 CCNP MAST2 ANKZF1 PDE4DIP OSBP2 SOS2	2.01e-04	198	137	7	3550_UP
Drug	Furaltadone hydrochloride [3759-92-0]; Down 200; 11uM; PC3; HT_HG-U133A	TRIOBP MAST2 BAZ2A PDE4DIP RERE PRRC2B JHY	2.01e-04	198	137	7	3756_DN
Drug	Heptaminol hydrochloride [543-15-7]; Up 200; 22uM; PC3; HT_HG-U133A	SIPA1L3 FRMPD1 SBNO2 OSBP2 RERE LONRF3 SOS2	2.01e-04	198	137	7	7313_UP
Drug	Ioversol [87771-40-2]; Up 200; 5uM; MCF7; HT_HG-U133A	SYNRG SAMD9 CASP9 SYBU SMG7 PDE4DIP FGFR2	2.01e-04	198	137	7	5326_UP
Drug	Iopamidol [60166-93-0]; Down 200; 5.2uM; PC3; HT_HG-U133A	SH3TC2 AP3B1 CEP350 VPS13D FGFR2 TRAPPC9 PRRC2B	2.07e-04	199	137	7	5832_DN
Drug	Triamcinolone [124-94-7]; Down 200; 10.2uM; MCF7; HT_HG-U133A	ARHGAP32 SIPA1L3 ANKZF1 SBNO2 KMT2A PLXNB1 PRRC2B	2.07e-04	199	137	7	7192_DN
Drug	Glimepiride [93479-97-1]; Up 200; 8.2uM; MCF7; HT_HG-U133A	ARHGEF28 ITGA8 BAZ2A KCNH2 VCAN KMT2A PLXNB1	2.07e-04	199	137	7	4973_UP
Drug	Nisoxetine hydrochloride [57754-86-6]; Up 200; 13uM; MCF7; HT_HG-U133A	ITGA8 CASP9 BAZ2A LONRF3 PLXNB1 JHY SOS2	2.07e-04	199	137	7	5516_UP
Drug	Nalidixic acid sodium salt hydrate; Down 200; 14.6uM; MCF7; HT_HG-U133A	SIPA1L3 TRIOBP ANKZF1 SBNO2 SMG7 BAZ2A SOS2	2.07e-04	199	137	7	4691_DN
Drug	Methoxy-6-harmalan [3589-73-9]; Down 200; 18.6uM; PC3; HT_HG-U133A	AAK1 ATP8B1 ANKZF1 ADD1 MAP7D1 PRRC2B JHY	2.07e-04	199	137	7	6355_DN
Drug	Urapidil hydrochloride [64887-14-5]; Down 200; 9.4uM; MCF7; HT_HG-U133A	SYNRG ARHGAP32 SIPA1L3 AP3B1 SBNO2 DZANK1 KMT2A	2.07e-04	199	137	7	5295_DN
Drug	(S)-(-)-Cycloserine [339-72-0]; Down 200; 39.2uM; MCF7; HT_HG-U133A	AAK1 SBNO2 BAZ2A RERE STRA6 LONRF3 PLXNB1	2.07e-04	199	137	7	4346_DN
Drug	haloperidol; Down 200; 10uM; MCF7; HT_HG-U133A	DNAJC13 AAK1 AP3B1 VPS13D ZNF592 MPHOSPH9 RERE	2.07e-04	199	137	7	6923_DN
Drug	prednisolone; Up 200; 1uM; MCF7; HG-U133A	ARHGEF28 ANKZF1 SBNO2 PDE4DIP BICRAL MPHOSPH9 FGFR2	2.07e-04	199	137	7	265_UP
Drug	Dimaprit dihydrochloride [23256-33-9]; Down 200; 17uM; MCF7; HT_HG-U133A	CASP9 AP3B1 DZANK1 KCNH2 TRAPPC9 PLXNB1 SOS2	2.13e-04	200	137	7	6520_DN
Drug	Diflorasone Diacetate [33564-31-7]; Down 200; 8uM; PC3; HT_HG-U133A	ZNF407 AP3B1 PDE4DIP OSBP2 FGFR2 PLXNB1 SOS2	2.13e-04	200	137	7	4077_DN
Drug	Sulfathiazole [72-14-0]; Up 200; 15.6uM; MCF7; HT_HG-U133A	IRS4 SIPA1L3 ZNF592 KCNH2 VCAN FGFR2 SOS2	2.13e-04	200	137	7	4769_UP
Drug	Cefotetan [69712-56-7]; Down 200; 7uM; PC3; HT_HG-U133A	FRMPD1 SBNO2 DZANK1 BAZ2A OSBP2 TRAPPC9 SOS2	2.13e-04	200	137	7	3997_DN
Drug	Epiandrosterone [481-29-8]; Down 200; 13.8uM; MCF7; HT_HG-U133A	CASP9 ANKZF1 PDE4DIP BICRAL FGFR2 LONRF3 SOS2	2.13e-04	200	137	7	5687_DN
Disease	cortical surface area measurement	DNAJC13 SAMD9 PCNX3 NBEAL1 TRIOBP SYBU MAST2 PKMYT1 ZNF469 EGFR VCAN RP1L1 MPHOSPH9 FGFR2 RERE SPAG17 EPHA4 EPHB1 SOS2	1.11e-05	1345	134	19	EFO_0010736
Disease	spastic quadriplegic cerebral palsy 3 (implicated_via_orthology)	ADD1 ADD3	6.12e-05	3	134	2	DOID:0081361 (implicated_via_orthology)
Disease	uric acid measurement	DNAJC13 UNCX PCNX3 SIPA1L3 AAK1 ZDHHC5 LMTK2 PIP5K1B BICC1 PRRC2B SOS2	1.12e-04	610	134	11	EFO_0004761
Disease	Endometrial adenocarcinoma	EGFR FGFR2	1.22e-04	4	134	2	C1153706
Disease	cortical thickness	NBEAL1 LAMA1 TRIOBP SYBU MAST2 ZNF469 VPS13D SMG7 EGFR VCAN FMN2 KMT2A RERE EPHA4 SOS2	1.68e-04	1113	134	15	EFO_0004840
Disease	urate measurement	DNAJC13 UNCX PCNX3 AAK1 LMTK2 CASP9 TTC7A FMN2 PIP5K1B BICC1 PRRC2B EPHA4 SOS2	2.28e-04	895	134	13	EFO_0004531
Disease	hearing loss	ARHGEF28 TRIOBP NOX4 MAST2	2.50e-04	67	134	4	EFO_0004238
Disease	neuroticism measurement	KLF8 OXR1 NBEAL1 ZDHHC5 LMTK2 DCAF8L1 RP1L1 KMT2A RERE HERC1 CMTR2 EPHA4 EPHB1	2.64e-04	909	134	13	EFO_0007660
Disease	heparan sulfate glucosamine 3-O-sulfotransferase 3A1 measurement	ZFPM2 ADD3	3.03e-04	6	134	2	EFO_0801671
Disease	hematocrit	STARD13 DNAJC13 UNCX NBEAL1 AAK1 ATP8B1 MAST2 SLC40A1 ZFPM2 PRR12 DZANK1 NFE2L1 BICC1	7.19e-04	1011	134	13	EFO_0004348
Disease	QT interval	ARHGEF28 MAST2 ZFPM2 TTC7B ZNF592 KCNH2 ROS1 NEURL4 PRRC2B	7.70e-04	534	134	9	EFO_0004682
Disease	cerebral palsy (implicated_via_orthology)	ADD1 ADD3	8.99e-04	10	134	2	DOID:1969 (implicated_via_orthology)
Disease	4-vinylphenol sulfate measurement	EPHB1 SOS2	8.99e-04	10	134	2	EFO_0021149
Disease	Head and Neck Carcinoma	EGFR FGFR2	8.99e-04	10	134	2	C3887461
Disease	complement factor H-related protein 3 measurement	VPS37A AAK1 LIFR SSC5D EPHA4	1.07e-03	169	134	5	EFO_0600056
Disease	schizophrenia, anorexia nervosa	ZNF592 MPHOSPH9 RERE	1.36e-03	48	134	3	MONDO_0005090, MONDO_0005351
Disease	restless legs syndrome	UNCX SLC40A1 PKMYT1	1.45e-03	49	134	3	EFO_0004270
Disease	amyotrophic lateral sclerosis (biomarker_via_orthology)	CASP9 KCNJ10	1.55e-03	13	134	2	DOID:332 (biomarker_via_orthology)
Disease	Skin Abnormalities	ZNF469 FGFR2	1.55e-03	13	134	2	C0037268
Disease	response to simvastatin, total cholesterol change measurement, response to fenofibrate	COG7 TRIOBP BICC1	1.63e-03	51	134	3	EFO_0007806, GO_1901557, GO_1903491
Disease	autosomal dominant polycystic kidney disease (is_marker_for)	FOS ITGA8	1.80e-03	14	134	2	DOID:898 (is_marker_for)
Disease	open-angle glaucoma	TRIOBP ZFPM2 KMT2A RERE BICC1	1.84e-03	191	134	5	EFO_0004190
Disease	Small cell carcinoma of lung	ZDBF2 EGFR KMT2A	1.92e-03	54	134	3	C0149925
Disease	creatinine measurement	KLF8 DNAJC13 UNCX SIPA1L3 CCNP CASP9 MAST2 SBNO2 ZNF592 NFE2L1 PIP5K1B SOS2	1.97e-03	995	134	12	EFO_0004518
Disease	creatinine measurement, glomerular filtration rate	UNCX SIPA1L3 CASP9 PIP5K1B	2.03e-03	117	134	4	EFO_0004518, EFO_0005208
Disease	Prostatic Neoplasms	SAMD9 TOM1L1 LMTK2 CASP9 LIFR EGFR BAZ2A KMT2A POLK	2.06e-03	616	134	9	C0033578
Disease	Malignant neoplasm of prostate	SAMD9 TOM1L1 LMTK2 CASP9 LIFR EGFR BAZ2A KMT2A POLK	2.06e-03	616	134	9	C0376358
Disease	cochlin measurement	ZFPM2 NFE2L1	2.36e-03	16	134	2	EFO_0801481
Disease	p-cresol sulfate measurement	STARD13 EPHA4	2.36e-03	16	134	2	EFO_0010998
Disease	smoking status measurement	SAMD9 TRPC4 LMTK2 ZNF407 MAST2 ADD1 ADD3 BICRAL RERE HERC1 UNC79 PRRC2B EPHB1	2.45e-03	1160	134	13	EFO_0006527
Disease	body surface area	EEF1AKMT4-ECE2 DYM UNCX AAK1 AP3B1 MAP7D1 KCNH2 UNC79 EPHA4	2.74e-03	643	134	9	EFO_0022196
Disease	hypertension (implicated_via_orthology)	MYBPH NOX4 ADD1 ADD3	2.81e-03	128	134	4	DOID:10763 (implicated_via_orthology)
Disease	central corneal thickness	MASP1 SAMD9 ZNF407 ZNF469 KMT2A BICC1	2.94e-03	309	134	6	EFO_0005213
Disease	transitional cell carcinoma (is_marker_for)	DAXX EGFR FGFR2	2.98e-03	63	134	3	DOID:2671 (is_marker_for)
Disease	Adrenocortical carcinoma	DAXX EGFR	2.99e-03	18	134	2	C0206686
Disease	Malignant neoplasm of endometrium	EGFR FGFR2	2.99e-03	18	134	2	C0007103
Disease	Carcinoma in situ of endometrium	EGFR FGFR2	2.99e-03	18	134	2	C0346191
Disease	osteochondrodysplasia (is_implicated_in)	DYM LIFR	3.33e-03	19	134	2	DOID:2256 (is_implicated_in)
Disease	response to COVID-19 vaccine, SARS-CoV-2 neutralizing antibody measurement	LMTK2 EGFR	3.69e-03	20	134	2	EFO_0803359, EFO_0803362
Disease	juvenile dermatomyositis	SYBU GPAT2	3.69e-03	20	134	2	EFO_0000557
Disease	stomach cancer (is_marker_for)	CASP9 DAXX FGFR2 EPHB1	4.07e-03	142	134	4	DOID:10534 (is_marker_for)
Disease	Intellectual Disability	KLF8 OXR1 LAMA1 RBM28 PRR12 FGFR2 STRA6	4.42e-03	447	134	7	C3714756
Disease	ceramide measurement	STARD13 OXR1 ATP8B1 EIF2D OSBP2	4.46e-03	235	134	5	EFO_0010222

Protein segments in the cluster

Peptide	Gene	Start	Entry
LFDLSRDPSESTPLT	ARSF	506	P54793
LPQLFDLSSDPDELT	ARSK	436	Q6UWY0
PSIAPLALDSADLSE	EIF2D	186	P41214
TLTDELPAFSLTPLE	COG7	611	P83436
ILPFELESPNVATSS	VCAN	1751	P13611
ATPPFSLLETSNETD	VCAN	3056	P13611
LSNPTTDLLEEFAPT	AAK1	871	Q2M2I8
TDLLEEFAPTAISAP	AAK1	876	Q2M2I8
TAFSFEDDTVPLSPL	ADD3	411	Q9UEY8
TPILSEDSLEPFNSL	BAZ2A	291	Q9UIF9
QLASPASFSPDILAD	CMTR2	11	Q8IYT2
EDVLFLASPLTFDPS	AASDH	231	Q4L235
SPLQSLAASLDAEPS	CCNP	26	Q9H8S5
LESFPPSEARSALEN	PDSS2	376	Q86YH6
RLLSDPELSATESPL	BICC1	676	Q9H694
ELSPAVLDSLESPLF	CDAN1	346	Q8IWY9
SLLSEEPLAPSSIDA	DAXX	531	Q9UER7
FLAPELPAVSEFSTS	HADHB	206	P55084
DFVPADILLLSSSEP	ATP8B1	206	O43520
IFPADILLLSSSDPD	ATP10A	176	O60312
VSLLDLDDFNPVSTP	AP3B1	816	O00203
LLFSPEVESLPVASS	NFE2L1	376	Q14494
SLDSNTPLFPEDSSV	NBEAL1	1336	Q6ZS30
LPPSARSEQLEELFS	RBM28	11	Q9NW13
ESSLFSTLTPPDDQI	KIAA1549	801	Q9HCM3
PDFNISRAESLPLSS	ARHGEF28	526	Q8N1W1
FPETLPESSLFSVEA	C8orf76	216	Q96K31
PLLDRSIPDFTAFTT	EPHB1	901	P54762
ARPSFSLVEDTTLEP	FGFR2	21	P21802
VSSTLVEDFPSASLP	MUC16	8281	Q8WXI7
VEDFPSASLPVTSLL	MUC16	8286	Q8WXI7
FSCLLLPTSETDLPV	MTRNR2L6	6	P0CJ73
SAVLEPFNLTSEPSD	IER3	126	P46695
SPRLDVSSDSFDPLL	LSM11	21	P83369
PSTSPDAESLFREAL	MAGEA4	96	P43358
DTASDSPFLILPLTF	KCNJ10	241	P78508
ALPESTDSSLENLPL	JHY	146	Q6NUN7
DVLRESFTLLPDTDP	JMY	941	Q8N9B5
SFTLLPDTDPLTRSI	JMY	946	Q8N9B5
ALDALRSVLPSFPDD	NEUROG1	111	Q92886
ATPESEEAFTLPLLN	FOS	231	P01100
PSATEDSLQPATDLL	ZFPM2	401	Q8WW38
NEIASFSLDPTLPSV	HERC1	2461	Q15751
DPFLASPTSDREIIA	KCNH2	346	Q12809
ALLDPSSPEFSAVVS	EPHA4	901	P54764
PLDLSLSLSLSLSPD	PCNX3	1966	Q9H6A9
TDFRPSATPEDLLAS	PLXNB1	776	O43157
DLVPSTPSLFEAASL	PIP5K1B	461	O14986
LDDRISFSPDSVLEP	MPHOSPH9	316	Q99550
ASDFSLPQVEPVDLS	KLF8	76	O95600
DSLLEDSLSAPFPAS	LMTK2	976	Q8IWU2
SSNRLTTLPPDFLES	LRIT3	161	Q3SXY7
KLSPFFTLDLSPTED	ARHGAP32	861	A7KAX9
TTSSAPLALLPLDSF	OSBP2	171	Q969R2
LTLPDSLTSAASPED	GORASP1	386	Q9BQQ3
AASPEDTPELSAFLR	ITGA8	881	P53708
PSLLQFTFSEDDPIL	NUP155	266	O75694
FRDLLLPPSSQDSEI	NOX4	381	Q9NPH5
TDSLFVLPSRDDATP	RBBP6	971	Q7Z6E9
SESFRPNLSDPSELL	OXR1	701	Q8N573
SFLLSPLELSDSEPV	EEF1AKMT4-ECE2	466	P0DPD8
ALTEDSIDDTFLPVP	EGFR	1076	P00533
SLQFLEDELESSPLP	BICRAL	81	Q6AI39
FPAPTSSSELKLLEE	DYM	41	Q7RTS9
DAAPAPASISLFDLS	ANKZF1	6	Q9H8Y5
PASISLFDLSADAPV	ANKZF1	11	Q9H8Y5
SFPLVPSASLESVDD	FRMPD1	851	Q5SYB0
FDQLDAISSLPTPSD	CASP9	326	P55211
PLLFDDLPPASSTDS	ILKAP	26	Q9H0C8
LPPEASLSLDSSEGL	GPAT2	251	Q6NUI2
TLALLAFDSPEESPF	GID8	146	Q9NWU2
ESPSLASVPTADELF	CEP350	2481	Q5VT06
LSSESELPSLPLFSE	AKNA	1171	Q7Z591
TSDDLLFSKESPLLP	DNAJC13	1406	O75165
SRTPETLLPFAEAEA	MAP7D1	811	Q3KQU3
PTLRDSDLLSPSDFK	MASP1	501	P48740
AEFISSNTPDSVLPL	MAST2	336	Q6P0Q8
FELPLELPSDLSVLT	KMT2A	2921	Q03164
LPDLVTESLFSSPEE	DCAF8L1	11	A6NGE4
SLALAAEEPRPFSES	DZANK1	401	Q9NVP4
SPDTEQALSALSDLP	FMN2	266	Q9NZ56
LPETLNSPLLETFSD	SLC22A15	481	Q8IZD6
ENLSPFDSIPDSELL	PPRC1	141	Q5VV67
FDSIPDSELLVSPRE	PPRC1	146	Q5VV67
VTALDPSVLDFPSSA	NEURL4	106	Q96JN8
AFSSFPPLSLLEEEA	DIPK1C	121	Q0P6D2
PDTPEILNLSADFST	LIFR	136	P42702
SAFPTDSLERDLSPS	IRS4	1101	O14654
DSLERDLSPSSAPAV	IRS4	1106	O14654
LCDPAESELSPFLIT	TAS2R39	21	P59534
FPKALSIESLSPTDS	STARD13	406	Q9Y3M8
TTSEPSAPSQDLLDL	TOM1L1	306	O75674
TPPVSASSDLSVFLD	SOS2	1091	Q07890
VSEDALPETTFPALA	SYNRG	951	Q9UMZ2
LSSVDDPRDPLIETF	SAMD9	546	Q5K651
AAVPPAEELAFTDSL	RABGGTA	156	Q92696
PSADDLSPKLLEFTS	LAMA1	206	P25391
DLSSISATPLPEEFE	SMG7	406	Q92540
VSLFSLNDPALSPDI	SIPA1L3	1666	O60292
VDSLSDIVDTPDFLP	SBNO2	111	Q9Y2G9
LLSATSDSYRLPEPD	SH3TC2	431	Q8TF17
SPLDLSVSPFEDIRS	SLC40A1	396	Q9NP59
PSAPLLLTLDDVSSS	MYBPH	71	Q13203
RPPSSEFLDLSSASE	RERE	476	Q9P2R6
ESISSAISALDDPPL	PRR12	1396	Q9ULL5
DLILTSPDFALSTPD	SSC5D	1061	A1L4H1
FPLPSSDLDDSLTEE	MSANTD4	96	Q8NCY6
EPSLLFQDLPRASTE	TRIOBP	1131	Q9H2D6
EDALPFLTLASAPSQ	STRA6	121	Q9BX79
IADLTPLLSFQATDP	SPAG17	1411	Q6Q759
DSDAATFKPTLPDLS	ADD1	631	P35611
FEELLSAETDTPLLP	RNF17	1386	Q9BXT8
LTALPDEFSPAVSQA	RNF213	4036	Q63HN8
ASSDQFLPSLEDPLA	TNRC18	1326	O15417
SRTTELPAADPFALA	nan	331	Q6ZSR9
LGPLSFTLEDEPALS	RP1L1	1626	Q8IWN7
PSFEPRNLLSLFEDT	PKMYT1	481	Q99640
SFPESLSALVVDLTP	SYBU	531	Q9NX95
TEPLLSFVASVSPAD	TUT1	826	Q9H6E5
SPDLITTLADLFSPS	SPATA31D1	201	Q6ZQQ2
DLLAAFDIPDPTSLD	ZNF592	11	Q92610
RSISPLLFEESPSDV	POLK	246	Q9UBT6
SSSELTFDSDPPLLS	ZDBF2	746	Q9HCK1
TFDSDPPLLSVTEQS	ZDBF2	751	Q9HCK1
RFSLEDPTPDIILSS	MYCBPAP	881	Q8TBZ2
SSRLLSFSPEEFPTL	PRRC2B	161	Q5JSZ5
SPLPEKSSSLLEESF	SH2D7	221	A6NKC9
LENADLPTAPFASSI	ROS1	96	P08922
DSPSSLFESLISPIK	RIOX2	36	Q8IUF8
DILLASPSSAFQPDT	SKOR2	11	Q2VWA4
TLESSSLFPDLPVDR	ZNF469	1421	Q96JG9
DSLLTPSDSPDFESV	ZDHHC5	471	Q9C0B5
FLTALELEASSPAVP	TTC7B	821	Q86TV6
FLTALELEASSPVLP	TTC7A	836	Q9ULT0
EFESLPAALSLPAES	TRAPPC9	626	Q96Q05
SILLFDSTQESLPPS	ZNF280C	141	Q8ND82
LEPALEDSSSFSPLD	TARBP2	101	Q15633
DSPFTAAALAEEPLV	ZNF407	1831	Q9C0G0
TSLPPATLEAIFDAD	VRTN	146	Q9H8Y1
EDFPLRLESAAPSQT	TRBV6-9	91	A0A0J9YX75
PSLIALSSEDPFLTA	TRPC4	206	Q9UBN4
DVPDAFPELSELSVS	VPS37A	226	Q8NEZ2
PGSPLLFDSTLDLET	TTF2	366	Q9UNY4
LPKASPFSVESLLSD	UNCX	326	A6NJT0
TSDSDSLVFEPLPPL	UNC79	1626	Q9P2D8
PIERESELTFSLSPD	VPS13D	1501	Q5THJ4
PALSLPLASFDASDL	LONRF3	451	Q496Y0
IPDPIAIASLSFLTS	ART4	291	Q93070
PPASTATLLSNDLEA	PDE4DIP	1761	Q5VU43